Navigation Links
Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012
Date:3/27/2013

duct and contract manufacturing revenues and restructuring charges, total operating expenses related to continuing operations for the year ended December 31, 2012 increased to $34.6 million (including share-based compensation of $1.0 million) from $30 million (including share-based compensation of $0.8 million) in the prior year.  For the year ended December 31, 2011, total operating expenses includes reimbursement of $1.1 million of legal fees during the first quarter of 2011 associated with the settlement of a noteholder lawsuit, which was recorded as an offset to operating expenses. Excluding this reimbursement, total operating expenses increased $3.5 million primarily due to increased research and development costs reflecting continued investment in pipeline products, additional depreciation and facility related costs associated with the Company's new headquarters beginning in June 2012 and transaction costs associated with various financing and strategic alternatives the Company was pursuing during the first quarter of 2012.

Gain on Sale of Oilseed Processing Business

On March 23, 2012, the Company entered into an asset purchase agreement with DSM for the purchase of the Company's oilseed processing business and concurrently entered into a license agreement, a supply agreement and a transition services agreement with DSM.  The aggregate consideration received by the Company was $37 million. The $31.3 million gain on sale for the year ended December 31, 2012 was calculated as the difference between the allocated consideration amount for the oilseed processing business, and the net carrying amount of the purchased assets and liabilities, net of transaction-related costs.

Income (Loss) from Operations

Income from operations for the year ended December 31, 2012 was $21.7 million compared to loss from operations of $6.2 million for the prior year, on a GAAP accounting basis.  Adjusted for the impact of restruc
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Verenium Announces Preliminary Financial Results For Fiscal 2012
2. Verenium To Present At The 25Th Annual Roth Conference
3. Verenium Appoints Holger Liepmann To Its Board Of Directors
4. Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
5. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
6. Verenium Announces $22.5 Million, Five-Year Secured Financing
7. Verenium Corporation To Announce Third Quarter 2012 Financial Results
8. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
11. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 /PRNewswire/ ... with Impressive Acheivements  DiaCardio wins 1 st place  ... The competition, led in Israel by ... 21 startups from countries including the US, China ... and Latin America .  Impressive achievement ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
(Date:8/25/2015)...   WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... Exchange Stock Code: 0950), a research-based biopharmaceutical company headquartered ... years of operations in China , ... agreement whereby WuXi,s Laboratory Testing Division (LTD) will be ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... Madison, Wis. - Madison Development Corp. (MDC) reported ... Debt" loans to three Madison technology companies since starting ... loan made earlier this month. , ,MDC, a non-profit ... technology businesses stretch local venture capital dollars. Since starting ...
... - At least six Wisconsin biotech companies will ... event that may be another signal of the rising ... ,The Wisconsin companies will travel to Minneapolis for the ... the Biotechnology Industry Organization . Companies will present ...
... Wis. - Industry trade publication DM Review ... 2005 World Class Solution Awards competition. , ,The award, ... data warehousing industry, has been given out since 1996. ... of the market as determined by feedback from DM ...
Cached Biology Technology:MDC "Venture Debt" loans help fund tech firms 2Six Wisconsin firms to present at BIO Mid-America VentureForum 2Six Wisconsin firms to present at BIO Mid-America VentureForum 3DM Review announces award finalists 2
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
(Date:8/24/2015)... Calif. , Aug. 24, 2015  Based on its ... recognizes DERMALOG with the 2015 African Biometrics Company of the ... has achieved substantial commercial success in Africa ... , where it has implemented one of the largest ... banks as well as the Central Bank of ...
(Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... Soccer players and exercise enthusiasts now have another reason ... workout, suggests a new study from James Madison University ... meeting. Post-exercise consumption of lowfat chocolate milk was ... compared to a high-carbohydrate recovery beverage with the same ...
... years modeled how different species are likely to respond ... populations within a species and the interactions between species, ... June issue of BioScience , by Eric Post ... these limitations can be avoided. Their approach, which relies ...
... LA JOLLA, CAA study led by researchers at the Salk ... medicine significantly forward, proving in principle that a human genetic ... and induced pluripotent stem (iPS) cell technology. The study, published ... Nature , is a major milestone on the path from ...
Cached Biology News:New study finds lowfat chocolate milk is effective post-exercise recovery aid for soccer players 2Combined stem cell-gene therapy approach cures human genetic disease in vitro 2
Intestinal Epithelium Differentiation Environment...
Hepatocyte Differentiation Environment...
... Useful as a positive control for ... to chromatin in vivo is a crucial ... extent of crosslinking is probably the most ... subsequent immunoprecipitation step should be taken into ...
... 300V (Cat. No. MP-300V) power supply is ... electrophoresis needs in a personal, single, easy ... power supply provides Constant Voltage or ... 4 pairs of terminator and the powerful ...
Biology Products: